 Soligenix Demonstrates Clinical Success in First-in-Class Treatment for Cutaneous T-Cell LymphomaNew York, New York--Newsfile Corp. - July 22, 2021 - PCG Digital -- Cutaneous T-cell lymphoma CTCL is a rare form of non-Hodgkins lymphoma that currently affects between 16,000 - 20,000 Americans, with approximately 1,000 new diagnoses each year. There is currently no FDA-approved first line treatment for CTCL, leaving clinicians and patients reliant on traditional phototherapy treatments. Soligenix NASDAQ: SNGX, a biopharmaceutical company specializing in treatments for rare diseases, is addressing this unmet need... 